AstraZeneca

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell AstraZeneca and other ETFs, options, and stocks.

About AZN

AstraZeneca Plc is a global, science-led biopharmaceutical company focused on the discovery, development, and commercialization of prescription medicines. Its portfolio spans oncology, rare diseases, and biopharmaceuticals, including cardiovascular, renal & metabolism, and respiratory & immunology. 

CEO
Pascal Soriot
CEOPascal Soriot
Employees
94,300
Employees94,300
Headquarters
Cambridge, Cambridgeshire
HeadquartersCambridge, Cambridgeshire
Founded
1913
Founded1913
Employees
94,300
Employees94,300

AZN Key Statistics

Market cap
324.67B
Market cap324.67B
Price-Earnings ratio
31.75
Price-Earnings ratio31.75
Dividend yield
1.52%
Dividend yield1.52%
Average volume
2.71M
Average volume2.71M
High today
$212.65
High today$212.65
Low today
$212.05
Low today$212.05
Open price
$208.11
Open price$208.11
Volume
11.45K
Volume11.45K
52 Week high
$212.65
52 Week high$212.65
52 Week low
$122.48
52 Week low$122.48

Stock Snapshot

AstraZeneca(AZN) stock is priced at $212.27, giving the company a market capitalization of 324.67B. It carries a P/E multiple of 31.75 and pays a dividend yield of 1.5%.

On 2026-02-18, AstraZeneca(AZN) stock traded between a low of $212.05 and a high of $212.65. Shares are currently priced at $212.27, which is +0.1% above the low and -0.2% below the high.

AstraZeneca(AZN) shares are trading with a volume of 11.45K, against a daily average of 2.71M.

In the last year, AstraZeneca(AZN) shares hit a 52-week high of $212.65 and a 52-week low of $122.48.

In the last year, AstraZeneca(AZN) shares hit a 52-week high of $212.65 and a 52-week low of $122.48.

AZN News

TipRanks 2h
Innate Pharma to Spotlight Cancer Immunotherapy Pipeline at Leerink Global Healthcare Conference

Innate Pharma SA ( (FR:IPH) ) has issued an update. Innate Pharma S.A., a clinical-stage biotech specializing in cancer immunotherapies and next-generation ant...

TipRanks 5d
AstraZeneca publishes KALOS, LOGOS trial data

Full results from the Phase III KALOS and LOGOS trials published in The Lancet Respiratory Medicine showed AstraZeneca’s (AZN) Breztri Aerosphere demonstrated s...

Analyst ratings

80%

of 30 ratings
Buy
80%
Hold
10%
Sell
10%

People also own

Based on the portfolios of people who own AZN. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.